The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 52, Issue 10, 2011, Pages 1913-1919

  Jakovic, Ljubomir R ^a   Mihaljevic, Biljana S ^a,b   Perunicic Jovanovic, Maja D ^a   Bogdanovic, Andrija D ^a,b   Andjelic, Bosko M ^a   Bumbasirevic, Vladimir Z ^b  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

advanced Hodgkin lymphoma; Macrophages

Indexed keywords

ALBUMIN; BLEOMYCIN; CD68 ANTIGEN; CD86 ANTIGEN; CISPLATIN; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; HEMOGLOBIN; VINBLASTINE;

ADULT; ADVANCED CANCER; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLASSICAL HODGKIN LYMPHOMA; CLINICAL ARTICLE; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; ERYTHROCYTE SEDIMENTATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTERNATIONAL PROGNOSTIC SCORE; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SCORING SYSTEM; TUMOR ASSOCIATED LEUKOCYTE;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 80053191591     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.580026     Document Type: Article

References (42)

1. Horning JS. Risk, cure and complications in advanced Hodgkin disease. Hematology Am Soc Hematol Educ Program 2007:197-203.
2. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327: 1478-1484.
3. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998;339:1506-1514. (Pubitemid 28543499)
4. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010;362:875-885.
5. Zender T, Wiedenmann S, Wolf J. Prognostic factors in Hodgkin's lymphoma. Ann Oncol 2002;13:67-74.
6. Ferme C, Bastion Y, Brice P, et al. Prognosis of patients with advanced Hodgkin's disease: evaluation of prognosis of four prognostic models using 344 patients included in the Group D'Etudes des Lymphomes de l'Adulte Study. Cancer 1997; 80:1124-1133. (Pubitemid 27427613)
7. Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, et al. Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites. Eur J Haematol 2001;67:279-288. (Pubitemid 34135440)
8. Gobbi PG, Zinzani PL, Broglia C, et al. Comparsion of prognostic models in patients with advanced Hodgkin's disease: promising results from integration of the best three systems. Cancer 2001;91:1467-1478. (Pubitemid 32319257)
9. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Costwold meeting. J Clin Oncol 1989;7:1630-1636. (Pubitemid 19272832)
10. Von Wasielewski R, von Wasielewski S, Franklin P, et al. Nodular sclerosing HD: a new proposal to distinguish highrisk patients. Leuk Lymphoma 2001;42(Suppl. 2):82.
11. Sup SJ, Alemany CA, Pohlman B, et al. Expression of Bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome. J Clin Oncol 2005;23:3773-3779.
12. Alvaro-Naranjo T, Leujeune M, Salvado-Usach MT, et al. Tumor infiltrating cells as prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk Lymphoma 2005;46:1581-1591. (Pubitemid 41700991)
13. Kelley TW, Pohlman B, Elson P, Hsi ED. The ratio of FOXP3p regulatory T cells to granzyme Bp cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol 2007;128:958-965.
14. Specht L. Tumour burden as the main indicator of prognosis in Hodgkin's disease. Eur J Cancer 1992;28A: 1982-1985.
15. Anderson H, Jenkins JP, Brigg DJ, et al. The prognostic significance of mediastinal bulk in patients with stage IA-IVB Hodgkin's disease: a report from a report from the Manchester Lymphoma Group. Clin Radiol 1985;36:449-454. (Pubitemid 15226789)
16. Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoetic and lymphoid tissues. 4th ed. Lyon:International Agency for Research on Cancer; 2008.
17. Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphomadiagnosis and treatment. Lancet Oncol 2004;5:19-26.
18. Juszczynski P, Ouyang J, Monti S, et al. The AP1-dependent secretion of galectin-1 by Reed-Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA 2007;104:13134-13139. (Pubitemid 351737605)
19. Lamprecht B, Kreher S, Anagnostopoulos I, et al. Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3a. Blood 2008;112:3339-3347.
20. Pinto A, Aldinucci D, Gloghini A, et al. The role of eosinophils in the pathobiology of Hodgkin's disease. Ann Oncol 1997;8:89-96.
21. Carbone A, Gloghini A, Gattei V, et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood 1995;85:780-789.
22. Aldinucci D, Lorenzon D, Olivo K, Rapana B, Gattei V. Interactions between tissue fibroblasts in lymph nodes and Hodgkin/Reed-Sternberg cells. Leuk Lymphoma 2004;45: 1731-1739. (Pubitemid 38997138)
23. Aldinucci D, Olivo K, Lorenzon D, et al. The role of interleukin-3 in classical Hodgkin's disease. Leuk Lymphoma 2005;46:303-311. (Pubitemid 40220389)
24. Aldinucci D, Lorenzon D, Cattaruzza L, et al. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/RANTES in tumour cell growth and microenvironmental interactions. In J Cancer 2008;122:769-776.
25. Cattaruzza L, Gloghini A, Olivo K, et al. Functional coexpression of interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: involvement of IL-7 in tumour cell growth and microenvironmental interactions of Hodgkin's lymphoma. Int J Cancer 2009; 125:1092-1101.
26. Buri C, Korner M, Scharli P, et al. CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the non-neoplastic leukocytic infiltrates of Hodgkin disease. Blood 2001;97:1543-1548. (Pubitemid 32217213)
27. Fischer M, Juremalm M, Olsson N, et al. Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer 2003;107:197-201. (Pubitemid 37152897)
28. Ohshima K, Karube K, Hamasaki M, et al. Differential chemokine, chemokine receptor and cytokine expression in Epstein-Barr virus-associated lymphoproliferative diseases. Leuk Lymphoma 2003;44:1367-1378. (Pubitemid 36764292)
29. Khan G. Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma? Exp Hematol 2006;34:399-406.
30. Re D, Thomas RK, Behringer K, Diehl V. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood 2005;105:4553-4560. (Pubitemid 40807270)
31. Aldinucci D, Poletto D, Nanni P, et al. Hodgkin and Reed- Sternberg cells express functional c-kit receptors and interact with primary fibroblasts from Hodgkin's disease-involved lymph nodes through soluble and membrane-bound stem cell factor. Br J Haematol 2002;118:1055-1064. (Pubitemid 35025969)
32. Aldinucci D, Poletto D, Gloghini A, et al. Expression of functional interleukin-3 receptors on Hodgkin and Reed- Sternberg cells. Am J Pathol 2002;160:585-596. (Pubitemid 34160336)
33. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor infiltrating immune cells. N Engl J Med 2004;351:2159-2169. (Pubitemid 39507628)
34. Burger JA, Ghia P, Rosenwald A, Caligaris-Capio F. The microenvoirement in mature B-cell malignancies: a target for new treatment strategies. Blood 2009;114:3367-3375.
35. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Nat Rev Immunol 2009;9:259-270.
36. Lin EY, Pollard JW. Tumor associated macrophages press the angiogenic switch in breast cancer. Cancer Res 2007;67:5064-5046.
37. De Vita VT, Costa J. Toward a personalized treatment of Hodgkin's disease. N Engl J Med 2010;362:942-943.
38. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009;9:15-27.
39. Aldinucci D, Gloghini A, Pinto A, et al. The classical Hodgkin's lymphoma microenvoirement and its role in promoting tumor growth and immune escape. J Pathol 2010;221:248-263.
40. Diehl V. Are macrophages the bad guys in Hodgkin lymphoma? Nature 2010;7:301-302.
41. Tzankov A, Matter MS, Dimhofer S. Refined prognostic role of CD68 positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma. Pathobiology 2010;77:301-308.
42. Kamper P, Bendix K, Hamilton-Dutoit S, Honore B, Nyengaard JR, d'Amore F. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 2011;96: 269-276.